KRIPNEROVA, M., H.S. PARMAR, Jiří ŠÁNA, Alena KOPKOVÁ, Lenka RADOVÁ, S. SOPPER, K. BIERNACKI, J. JEDLICKA, M. KOHOUTOVA, J. KUNCOVA, J. PEYCHL, E. RUDOLF, M. CERVINKA, Z. HOUDEK, P. DVORAK, K. HOUFKOVA, M. PESTA, Z. TUMA, M. DOLEJSOVA, F. TICHANEK, V. BABUSKA, M. LEBA, Ondřej SLABÝ and J. HATINA. Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model. Journal of Clinical Medicine. Basel: MDPI, 2021, vol. 10, No 11, p. 2297-2324. ISSN 2077-0383. Available from: https://dx.doi.org/10.3390/jcm10112297.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model
Authors KRIPNEROVA, M., H.S. PARMAR, Jiří ŠÁNA (203 Czech Republic, belonging to the institution), Alena KOPKOVÁ (203 Czech Republic, belonging to the institution), Lenka RADOVÁ (203 Czech Republic, belonging to the institution), S. SOPPER, K. BIERNACKI, J. JEDLICKA, M. KOHOUTOVA, J. KUNCOVA, J. PEYCHL, E. RUDOLF, M. CERVINKA, Z. HOUDEK, P. DVORAK, K. HOUFKOVA, M. PESTA, Z. TUMA, M. DOLEJSOVA, F. TICHANEK, V. BABUSKA, M. LEBA, Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution) and J. HATINA.
Edition Journal of Clinical Medicine, Basel, MDPI, 2021, 2077-0383.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.964
RIV identification code RIV/00216224:14740/21:00119079
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.3390/jcm10112297
UT WoS 000660208500001
Keywords in English fibrosarcoma; progression series; invasiveness; transcriptome; Ccl8
Tags 14110513, CF GEN, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 9/2/2022 13:18.
Abstract
Sarcomas are a heterogeneous group of mesenchymal tumours, with a great variability in their clinical behaviour. While our knowledge of sarcoma initiation has advanced rapidly in recent years, relatively little is known about mechanisms of sarcoma progression. JUN-murine fibrosarcoma progression series consists of four sarcoma cell lines, JUN-1, JUN-2, JUN-2fos-3, and JUN-3. JUN-1 and -2 were established from a single tumour initiated in a H2K/v-jun transgenic mouse, JUN-3 originates from a different tumour in the same animal, and JUN-2fos-3 results from a targeted in vitro transformation of the JUN-2 cell line. The JUN-1, -2, and -3 cell lines represent a linear progression from the least transformed JUN-2 to the most transformed JUN-3, with regard to all the transformation characteristics studied, while the JUN-2fos-3 cell line exhibits a unique transformation mode, with little deregulation of cell growth and proliferation, but pronounced motility and invasiveness. The invasive sarcoma sublines JUN-2fos-3 and JUN-3 show complex metabolic profiles, with activation of both mitochondrial oxidative phosphorylation and glycolysis and a significant increase in spared respiratory capacity. The specific transcriptomic profile of invasive sublines features very complex biological relationships across the identified genes and proteins, with accentuated autocrine control of motility and angiogenesis. Pharmacologic inhibition of one of the autocrine motility factors identified, Ccl8, significantly diminished both motility and invasiveness of the highly transformed fibrosarcoma cell. This progression series could be greatly valuable for deciphering crucial aspects of sarcoma progression and defining new prognostic markers and potential therapeutic targets.
Links
GA17-17636S, research and development projectName: Identifikace nových prognostických markerů a terapeutických cílových molekul u sarkomu měkkých tkání
Investor: Czech Science Foundation
LM2018132, research and development projectName: Národní centrum lékařské genomiky (Acronym: NCLG)
Investor: Ministry of Education, Youth and Sports of the CR, National Center for Medical Genomics
PrintDisplayed: 17/7/2024 07:13